IP Library Granted Patent US 11,958,854
Granted Patent B2
US 11,958,854 · App. 17/523,838 · Granted Apr 16, 2024

Substituted xanthines and methods of use thereof

Inventors: Bertrand L. Chenard (Waterford, CT); Randall J. Gallaschun (Lebanon, CT)
Assignee: Hydra Biosciences, LLC
C07D473/04C07D473/06C07D487/04C07D487/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,958,854
App. No.
17/523,838
Granted
Apr 16, 2024
Kind
B2
Abstract

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

Claims (21)

1. A method of treating a TRPC5 mediated disorder in a subject, the method comprising administering to the subject a compound of the formula:

or a pharmaceutically acceptable salt thereof, to thereby treat the subject;

wherein the TRPC5 mediated disorder is major depression.

2. The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

7. A method of treating a TRPC5 mediated disorder in a subject, the method comprising administering to the subject a compound of the formula:

to thereby treat the subject;

wherein the TRPC5 mediated disorder is major depression.

8. The method of claim 7 , wherein the compound is of the formula:

9. The method of claim 7 , wherein the compound is of the formula:

10. The method of claim 7 , wherein the compound is of the formula:

11. The method of claim 7 , wherein the compound is of the formula:

12. The method of claim 7 , wherein the compound is of the formula:

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2025
From: HYDRA BIOSCIENCES, LLC
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 072599/0843 →
MERGER Recorded May 24, 2022
From: HYDRA BIOSCIENCES, INC.
To: HYDRA BIOSCIENES, LLC
Reel/Frame 060001/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2022
From: CHENARD, BERTRAND L.; GALLASCHUN, RANDALL J.
To: HYDRA BIOSCIENCES, INC.
Reel/Frame 060175/0099 →
Continuity (7)
Continuation 16397697 · Apr 29, 2019
Continuation 15968941 · May 2, 2018
Continuation 15622838 · Jun 14, 2017
Continuation 15137327 · Apr 25, 2016
Continuation 14210781 · Mar 14, 2014
Provisional Application 61789724 · Mar 15, 2013
Related Publication 20230040259A1 · Feb 9, 2023